Department of Justice Drug Demand Reduction Activities

Report No. 03-12
February 2003
Office of the Inspector General




The OIG, Audit Division, conducted an audit to identify and review the DOJ's drug demand reduction activities. Specifically, the objectives of the audit were to (1) identify all DOJ programs that related to drug demand reduction, to quantify the total amount of DOJ obligations for each program, and to verify that financial information provided to the Office of the National Drug Control Policy (ONDCP)31 was prepared in accordance with its circulars; (2) determine whether the DOJ performance measures are adequate to determine the success of programs; (3) identify whether DOJ drug demand reduction activities were duplicative and whether DOJ components were coordinating drug demand reduction efforts; and (4) review the DEA activities and funding dedicated to drug demand reduction.

In this audit, we conducted approximately 50 interviews with over 60 officials from the BOP, COPS Office, DEA, OJP, OLP, JMD, and ONDCP. Additionally, we conducted fieldwork at the DEA Rocky Mountain Field Division and the BOP Florence Federal Correctional Institute. We also reviewed DOJ policies and procedures, program information, strategic and program plans, budget documentation, organizational structures, Congressional testimony, and prior OIG and General Accounting Office reports related to drug demand reduction.

We conducted our audit in accordance with Government Auditing Standards. We included such tests as were necessary to accomplish the audit objectives.

The audit generally covered, but is not limited to, the period of FY 2000 to the present. Audit work was conducted at the BOP, COPS Office, DEA, OJP, OLP, ONDCP, and selected field site locations.

To identify all DOJ drug demand reduction programs and the total amount of obligations for each program, we reviewed the FY 2001 DOJ Management Assertion Statements submitted to the ONDCP. For each of the four components identified, the BOP, COPS Office, DEA, and OJP, we reviewed the documentation supporting the Management Assertion Statements and interviewed program officials within each component to identify the programs included as drug demand reduction.

To identify the program missions, strategic goals, and objectives, for the each of the 20 DOJ programs reported as drug demand reduction, we interviewed program officials; and obtained: (1) the components' budget submissions for the OMB; (2) the strategic plans for each component, if available; (3) the DOJ strategic plan for those components that did not develop its own strategic plan; and (4) other program documentation. We reviewed the information to determine whether the programs were directly related to drug demand reduction based on the programs mission, strategic goals, and objectives.

Additionally, for the BOP, COPS Office, DEA, OJP we obtained the Management Assertion Statement submitted to the ONDCP for FY 2001, the Attestation Report prepared by the certified public accounting firm and supporting documentation, to determine the component's methodology for reporting drug demand reduction drug?related financial information and whether the information provided to the ONDCP was prepared in accordance with ONDCP circulars, reviewed by a independent certified public accounting firm, and appeared reasonable.

To assess whether the DOJ performance measures are adequate to determine the success of programs (i.e., outcome based measures rather than output based measures), we obtained the performance indicators for each program from the components budget submission for the OMB and reviewed the performance indicators to determine whether the performance indicators were: (1) supported with adequate data; (2) consistent with the drug treatment programs strategic goals, objectives and mission; and (3) output based, measuring the number of tasks or activities of a program or outcome based, measuring results and outcomes of program activities.

To identify those programs that address similar drug demand reduction purpose areas, we distributed questionnaires to program officials for each of the 10 DOJ programs identified as drug demand reduction. Based on the responses to the questionnaires, we identified the number of programs that either directly or indirectly address similar purpose areas. In conjunction with the questionnaires, we reviewed the mission, strategic goals, and objectives for each program to identify those programs that directly addressed similar purpose areas. Additionally, for those programs that provide overlapping drug demand reduction services, we obtained a listing of sites for each program to identify any duplication of efforts.

Finally, to identify the extent of coordination of the DOJ drug demand reduction efforts, we interviewed program officials and distributed questionnaires for each of the 10 DOJ programs identified as drug demand reduction.


  1. The ONDCP is a component within the Executive Office of the President of the United States, and is not a part of the DOJ. The ONDCP was created to set national drug control priorities and implement the National Drug Control Strategy.